{"title":"Long-term observation of a piebald patient showing pigmentation within leukoderma.","authors":"Megumi Mizawa, Teruhiko Makino, Tadamichi Shimizu","doi":"10.1684/ejd.2024.4691","DOIUrl":"10.1684/ejd.2024.4691","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"317-318"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Multiple squamous cell carcinomas in situ in a patient with lung cancer treated with tepotinib.","authors":"Toshiki Okazaki, Taku Fujimura, Yoshihide Asano","doi":"10.1684/ejd.2024.4694","DOIUrl":"10.1684/ejd.2024.4694","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"313-314"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
José Luis López Estebaranz, Carlos Maldonado González-Montagut, Jacob González, Inmaculada Aparicio García San Miguel, Veronica Garcia-Recio, Daniel Callejo, Anna De Prado, Carine Delattre
The European prevalence of vitiligo diagnosis is 0.2%-0.8%, with country-specific and methodological differences. Although vitiligo profoundly impacts quality of life, limited studies have evaluated disease burden and treatment patterns. This real-world study describes the prevalence, incidence, characteristics, and treatment patterns of vitiligo among patients in Spain during 2015-2021. This retrospective observational study using the IQVIA Electronic Medical Records database in Spain included patients with vitiligo (International Classification of Diseases, Ninth Revision codes 709.01/374.53). Incident and prevalent cohorts comprised registered patients with vitiligo diagnoses during and before 2015-2021, respectively. Patient characteristics and treatment data were extracted. Vitiligo incidence was 0.016 (95% CI: 0.014-0.018) per 100 person-years, and prevalence was 0.19% (95% CI: 0.18%-0.19%) in 2021. Females were more affected than males (0.16% vs 0.13%, respectively). Among 1,400 incident patients, mean (SD) age was 40.7 (19.7) years; most were female (53.9%). The most common comorbidities after vitiligo diagnosis were eczema (20.8%), hypercholesterolaemia/hypertriglyceridaemia (17.9%), anxiety (10.9%), thyroid disorders (9.1%), and diabetes (6.4%). In 2021, 78.6% of prevalent patients did not receive vitiligo-related treatments. The most prescribed vitiligo-related treatments were topical calcineurin inhibitors (13.9%) and topical corticosteroids (13.0%); 11.9% had a record of psychiatric medications. This study confirms the association between vitiligo and comorbidities (e.g., eczema, thyroid disorders) and high disease burden. The prevalence in Spain in 2021 (0.19%) was within the lower band of European estimates based on surveys/medical screenings. Most patients are not receiving vitiligo-related treatment and could benefit from new, effective treatments.
{"title":"Real-world evidence for vitiligo using an electronic medical records database in Spain: the REVEAL-ES study.","authors":"José Luis López Estebaranz, Carlos Maldonado González-Montagut, Jacob González, Inmaculada Aparicio García San Miguel, Veronica Garcia-Recio, Daniel Callejo, Anna De Prado, Carine Delattre","doi":"10.1684/ejd.2024.4676","DOIUrl":"10.1684/ejd.2024.4676","url":null,"abstract":"<p><p>The European prevalence of vitiligo diagnosis is 0.2%-0.8%, with country-specific and methodological differences. Although vitiligo profoundly impacts quality of life, limited studies have evaluated disease burden and treatment patterns. This real-world study describes the prevalence, incidence, characteristics, and treatment patterns of vitiligo among patients in Spain during 2015-2021. This retrospective observational study using the IQVIA Electronic Medical Records database in Spain included patients with vitiligo (International Classification of Diseases, Ninth Revision codes 709.01/374.53). Incident and prevalent cohorts comprised registered patients with vitiligo diagnoses during and before 2015-2021, respectively. Patient characteristics and treatment data were extracted. Vitiligo incidence was 0.016 (95% CI: 0.014-0.018) per 100 person-years, and prevalence was 0.19% (95% CI: 0.18%-0.19%) in 2021. Females were more affected than males (0.16% vs 0.13%, respectively). Among 1,400 incident patients, mean (SD) age was 40.7 (19.7) years; most were female (53.9%). The most common comorbidities after vitiligo diagnosis were eczema (20.8%), hypercholesterolaemia/hypertriglyceridaemia (17.9%), anxiety (10.9%), thyroid disorders (9.1%), and diabetes (6.4%). In 2021, 78.6% of prevalent patients did not receive vitiligo-related treatments. The most prescribed vitiligo-related treatments were topical calcineurin inhibitors (13.9%) and topical corticosteroids (13.0%); 11.9% had a record of psychiatric medications. This study confirms the association between vitiligo and comorbidities (e.g., eczema, thyroid disorders) and high disease burden. The prevalence in Spain in 2021 (0.19%) was within the lower band of European estimates based on surveys/medical screenings. Most patients are not receiving vitiligo-related treatment and could benefit from new, effective treatments.</p>","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"251-259"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"sQuiz your knowledge! A keratotic nodule on a chronic burn scar.","authors":"Qiaochu Zhou, Shan Zhang, Wenru Li","doi":"10.1684/ejd.2024.4721","DOIUrl":"10.1684/ejd.2024.4721","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"348-350"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"X-linked hypohidrotic ectodermal dysplasia with a deletion in exon 2 of the EDA gene: a case report and literature review.","authors":"Shengzhao Chen, Xiaoshuang Yang, Zhongfa Lu","doi":"10.1684/ejd.2024.4696","DOIUrl":"10.1684/ejd.2024.4696","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"310-311"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Estelle Bulte, Marion Douxami, Sophie Duvert-Lehembre, Edouard Massip
{"title":"Bullous pemphigoid associated with cutaneous adnexal carcinoma.","authors":"Estelle Bulte, Marion Douxami, Sophie Duvert-Lehembre, Edouard Massip","doi":"10.1684/ejd.2024.4690","DOIUrl":"10.1684/ejd.2024.4690","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"306-308"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eleonore Barthalon, Gwendy Dupire, Andreea Calugareanu, Benoit Ben Said
{"title":"Pamidronate-induced SDRIFE confirmed by skin testing without cross reactivity to zoledronate.","authors":"Eleonore Barthalon, Gwendy Dupire, Andreea Calugareanu, Benoit Ben Said","doi":"10.1684/ejd.2024.4699","DOIUrl":"10.1684/ejd.2024.4699","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"304"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Satoshi Yoshida, Ken Shiraishi, Kazuki Yatsuzuka, Nobushige Kohri, Jun Muto, Masamoto Murakami, Yasuhiro Fujisawa
Cholinergic urticaria with hypohidrosis or anhidrosis (CUHA) can impair quality of life due to itching, tingling, and reduced sweating. Current treatment options for CUHA include antihistamines, pulsed steroids, and sweat-promoting therapies such as exercise or hot baths. However, the efficacy of these therapies, particularly hot bath therapy, has yet to be established. We evaluated the efficacy of hot bath therapy in patients with CUHA. We enrolled eight patients who underwent hot bath therapy between January 2010 and August 2022. Patients had a half-body bath in a bathtub filled with hot water (40-43°C) for 30-60 minutes daily for 3-7 days. After treatment, pain improved in three (42.9%) patients, urticaria improved in four (50%) patients, and anhidrosis improved in five (62.5%) patients without any severe adverse events. Because hot bath therapy is easily performed, it should be considered a treatment option for patients with CUHA.
{"title":"Effects of hot bath therapy on cholinergic urticaria with hypohidrosis or anhidrosis.","authors":"Satoshi Yoshida, Ken Shiraishi, Kazuki Yatsuzuka, Nobushige Kohri, Jun Muto, Masamoto Murakami, Yasuhiro Fujisawa","doi":"10.1684/ejd.2024.4677","DOIUrl":"https://doi.org/10.1684/ejd.2024.4677","url":null,"abstract":"<p><p>Cholinergic urticaria with hypohidrosis or anhidrosis (CUHA) can impair quality of life due to itching, tingling, and reduced sweating. Current treatment options for CUHA include antihistamines, pulsed steroids, and sweat-promoting therapies such as exercise or hot baths. However, the efficacy of these therapies, particularly hot bath therapy, has yet to be established. We evaluated the efficacy of hot bath therapy in patients with CUHA. We enrolled eight patients who underwent hot bath therapy between January 2010 and August 2022. Patients had a half-body bath in a bathtub filled with hot water (40-43°C) for 30-60 minutes daily for 3-7 days. After treatment, pain improved in three (42.9%) patients, urticaria improved in four (50%) patients, and anhidrosis improved in five (62.5%) patients without any severe adverse events. Because hot bath therapy is easily performed, it should be considered a treatment option for patients with CUHA.</p>","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"271-275"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sokounthie Ou, Maéva Rodriguez, Pauline Baillard, Jean Kanitakis, Marie Danset
{"title":"Mucinous carcinoma, a rare breast carcinoma diagnosed during dermatological examination.","authors":"Sokounthie Ou, Maéva Rodriguez, Pauline Baillard, Jean Kanitakis, Marie Danset","doi":"10.1684/ejd.2024.4714","DOIUrl":"10.1684/ejd.2024.4714","url":null,"abstract":"","PeriodicalId":11968,"journal":{"name":"European Journal of Dermatology","volume":"34 3","pages":"320-322"},"PeriodicalIF":2.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号